Searched for
ELI LILLY
USFDA ends inspection of Aurobindo Pharma arm's facility with 4 observationsAurobindo Pharma announced its subsidiary Lannett Company LLC's facility inspection concluded. The US Food and Drug Administration conducte...- Eli Lilly launches oral weight-loss pill Foundayo in UKEli Lilly has launched its oral weight management pill Foundayo in the United Kingdom. This new treatment, chemically known as orforglipron...
- Nestle looks to develop new products to serve users of weight-loss drugsNestle is developing specialized products for GLP-1 weight-loss drug users. Artificial intelligence aids in analyzing research and identify...
- In 2020, Alzheimer’s diagnose process received major breakthrough approval, six years later 7 million patient in U.S. get another big announcement for progressive brain disease treatmentMore than 7 million people in the United States have Alzheimer's, and the number of people aged 65 or older with the disease could exceed ...
- UK first in Europe to approve Eli Lilly oral weight loss drugBritain has become the first country in Europe to approve orforglipron, the oral weight loss and diabetes treatment developed by US company...
- Eli Lilly’s Foundayo becomes first oral weight-loss drug approved in UK for diabetesBritain's regulator approved Eli Lilly's Foundayo pill for weight and diabetes. This treatment is not yet available through the NHS in the ...
- US stocks: Dow closes at record on Mideast optimism; SpaceX, AMD drag NasdaqThe Dow Jones Industrial Average achieved an all-time high on Wednesday, driven by rising optimism over potential peace talks with Iran. Me...
- Why US markets are rising: S&P 500, Dow hit record highs as Mideast hopes offset SpaceX, AMD dragMajor Wall Street indexes opened higher on Wednesday morning. Hopes for Middle East peace offset declines in SpaceX and AMD shares. These c...
- Global Market: European shares climb as earnings, US-Iran diplomacy lift sentimentEuropean stocks advanced on Wednesday, driven by U.S.-Iran diplomatic talks. Mining companies led the rally as geopolitical concerns eased ...
- Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipelineNovo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline afte...
- US Stock Market: Wall Street braces for jobs data, earnings as markets seek fresh directionInvestors await crucial July employment data and corporate earnings reports this week. Markets are navigating geopolitical tensions and int...
- Wall Street Week Ahead: Teetering US stock market faces jobs report, big earnings weekInvestors await US employment data and corporate results this week. Market direction remains uncertain due to geopolitical tensions and int...
- Alembic Pharma gets USFDA approval for generic chronic constipation treatment tabletsAlembic Pharmaceuticals announced USFDA approval for its generic prucalopride tablets. The company received final approval for strengths of...
- US market drag keeps Dr Reddy's, Cipla under pressure despite strong product pipelineIndian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...
- With a little help from pharma friends: Psychedelics for psychiatric therapyEli Lilly's acquisition signals a return of psychedelic drugs for mental health. These compounds offer a new approach to rewiring neural co...
- Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug adsNovo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers...
- Cipla in no hurry to launch semaglutide as Yurpeak gains tractionCipla is focusing on its tirzepatide brand Yurpeak in India's obesity market. Yurpeak has become the second largest GLP-1 product since its...
- Novo Nordisk sues Eli Lilly, accusing it of false advertising of weight-loss drugNovo Nordisk has sued Eli Lilly in a U.S. court. The Danish company accuses Lilly of false advertising for its weight-loss medicines. Novo ...
- Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley dealEli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental...
- Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: ReportEli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge follow...
Load More
